Published in Health Business Week, December 4th, 2009
4SC AG (Frankfurt, Prime Standard: VSC), a drug discovery and development company, announced the successful completion of a capital increase, after the Management Board, with the approval of the Supervisory Board, passed a resolution to authorise an increase of share capital on 23 October, 2009. The capital increase from the authorised capital included a collateral rights offering to existing shareholders at a subscription price of EUR3.00 per share. The remaining unsubscribed shares were allocated through a private placement in order to raise in the range of EUR25 to 30 million proceeds. The...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
Source: Health Business Week (2009-12-04)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.